<DOC>
	<DOCNO>NCT00869778</DOCNO>
	<brief_summary>The purpose evaluate efficacy safety therapeutic Hepatitis B Virus（HBV） vaccine ( mimogen-based ) treatment chronic hepatitis B patient explore effective dosage provide rational optimal dosing schedule .</brief_summary>
	<brief_title>Phase 2 Trial Therapeutic Hepatitis B Vaccine ( Mimogen-based ) Chronic Hepatitis B</brief_title>
	<detailed_description>First stage ( 0-76 week ) : Eligible subject enrol assigned 3 group randomly 1:1:1 ratio： 1. εPA-44 600μg group：Subcutaneous inject εPA-44 600μg week 0 , 4 , 8 , 12 , 20 , 28；Polyene Phosphatidylcholine Capsules take orally begin week 28 . 2. εPA-44 900μg group：Subcutaneous inject εPA-44 900μg week 0 , 4 , 8 , 12 , 20 , 28；Polyene Phosphatidylcholine Capsules take orally begin week 28 . 3 . Placebo control group：Subcutaneous inject empty liposome week 0 , 4 , 8 , 12 , 20 , 28；Polyene Phosphatidylcholine Capsules take orally begin week 28 . The study cycle consist screen enrollment period ( week -6-0 ) , treatment period ( week 0-28 ) follow-up period ( week 28-76 ) . Second stage ( 76-144 week ) : In follow-up stage trial open design , subject complete first stage study ( 0-76 week ) : 1 . Subjects virological response serological response first stage , refuse continue follow-up study , provide domestic Adefovir Dipivoxil one year freely ; 2 . Subjects virological response serological response/with serological response virological response/neither virological serological response first stage , willing continue follow-up study , treat εPA-44 900 μg； 3 . Subjects virological serological response , followed-up 144 week Adefovir Dipivoxil εPA-44 900 μg treatment . The definition response define : 1 . Virological response : HBV DNA＜2.93×10∧3IU/ml 76 week ; 2 . Serological response : serological conversion HBeAg 76 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Aged 1865 year , male female 2 . Conforms diagnosis standard chronic hepatitis B accord '' 2005 Guideline Prevention Treatment Hepatitis B '' , ( positive HBsAg 6 month ) , HBVDNA 100000 copies/ml ; HBeAg ( + ) , HBsAb ( ) ; Alanine aminotransferase（ALT） within 2 10 time ULN ( upper limit normal ) 3 . HLAA2 positive 4 . Compensatory liver disease follow hematological biochemical indicator : WBC≥3.5E+9/L ; ANC≥1.5E+9/L ; PLT≥80E+9/L ; Hb≥110g/L ; TBil≤1.5ULN ; ALB ≥ low limit normal value ; BUN ( Urea ) ≤upper limit normal value ; Cr≤upper limit normal value ; prothrombin time ( PT ) elongation≤3 sec ; Activated partial thromboplastin time（APTT） within normal value ; Fasting blood glucose≤7.0mmol/L 5 . TSH within normal value 6 . AFP ≤20ng/ml 7 . Uses effective contraception subject childbearing potential ( include female female partner male ) 8 . Understands sign ICF approve EC 9 . Willing comply study procedure complete study 1 . Antibody HAV IgM , HCV , HDV IgM HEV IgM positive 2 . Antibody CMV IgM , EBV IgM HIV positive 3 . Antinuclear antibody titer＞1:160 4 . Hepatocarcinoma , suspect hepatocarcinoma hepatic cirrhosis 5 . Has follow illness severe disease inappropriate participation study base investigator 's judgment , : Cardiovascular system : instable significant cardiovascular illness angina pectoris , heart attack myocardial infarction , congestive heart failure , severe hypertension , significant arrhythmia abnormal ECG etc . ; Respiratory system : bronchiectasis , bronchial asthma , chronic obstructive pulmonary disease , respiratory failure , etc . ; Endocrine , metabolism disease : diabetes mellitus , uncontrolled thyroid disease , etc . ; Others : autoimmune disorder , active tuberculosis , malignancy ( e.g.tumor ) , neuropathic metal illness history , etc . 6 . Has use antiHBV drug ( Interferon , Lamivudine , Adefovir Dipivoxil , Entecavir Telbivudine ) immunomodulator ( Thymic peptide , etc ) 6 month prior administration study medication 7 . Has participate drug clinical investigation within past 3 month 8 . Has allergy habitus suspect allergy study drug 9 . Female pregnancy , lactation planning become pregnant course study 10 . Has history alcohol abuse ( Alcohol consumption 5 year , daily consumption 40g male 20g female ) know drug dependence 11 . Has history organ transplant ( except external corneal transplantation hair transplantation ) 12 . Any factor inappropriate enrollment study study completion view investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>HBeAg positive</keyword>
	<keyword>Therapeutic HBV Vaccine</keyword>
	<keyword>HBV-specific Cytotoxic T Lymphocyte</keyword>
</DOC>